Anti-angiogenic therapy: Pro-angiogenic growth factors produced by tumour cells can downregulate the expression of a collection of adhesion molecules (e.g., VCAM-1 and ICAM-1), inhibiting extravasation of T lymphocytes across the tumour endothelium [2,157]. The gene discussed is VCAM1; the disease is neoplasm.